Costs and effects based on various scenarios
| With angiographic follow up | Without angiographic follow up | |||||
|---|---|---|---|---|---|---|
| Sirolimus stent (n = 120) | Bare stent (n = 118) | Difference | Sirolimus stent (n = 120) | Bare stent (n = 118) | Difference | |
| MACE, major adverse cardiac events. | ||||||
| Clinical events | ||||||
| Death | 1.7% | 1.7% | 0 | 1.7% | 1.7% | 0 |
| Myocardial infarction | 3.3% | 5.1% | −1.8% | 3.3% | 5.1% | −1.8 |
| Target lesion revascularisations | 0.8% | 23.6% | −22.8% | 0.8% | 11.8% | −11 |
| Surgical | 0.8% | 0.8% | 0 | 0.8% | 0.3% | 0.5 |
| Percutaneous | 0.0% | 22.9% | −22.9% | 0.0 | 11.5% | −11.5 |
| MACE-free survival | 94.2% | 71.2% | 23.0% | 94.2% | 83.1% | 11.1% |
| 95% CI | 89.9 to 98.4 | 62.9 to 79.4 | 13.7 to 32.2 | 88.9 to 97.5 | 64.2 to 90.9 | 1.7 to 28.0 |
| Angiography | 8.3% | 10.2% | −1.9% | 10.3% | 14.1% | −3.8% |
| Total direct medical cost (€) | 9969 | 9915 | 54 | 8065 | 7899 | 166 |
| 95% CI | 8910 to 10504 | 8722 to 10449 | −1054 to 1296 | 7052 to 9463 | 6821 to 9591 | −1376 to 1487 |